Evaluation of Sodium Butyrate as an Anti-fibrotic Agent in Experimental Schistosomiasis mansoni infection
Mansoura Medical Journal · 01.01.2026 · 56 (2)
DOI: 10.58775/2735-3990.1604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mansoura Medical Journal, online erschienen am 01.01.2026. Verfasst von Rania Eladl Hassan und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Schistosomiasis is a prominent neglected tropical disease that is caused by Schistosoma mansoni, and it is characterized by granuloma formation, which advances to hepatic fibrosis and serious liver damage. The standard medication is praziquantel (PZQ), but it has minimal effect on larvae and no effect on fibrosis which is a main pathological feature in schistosomiaiss. So, new alternatives were suggested, such as sodium butyrate (SB), which is a fatty acid salt with medicinal qualities.
Objective
This study investigated the anti-fibrotic effect of sodium butyrate (SB) in a mouse model of S. mansoni-induced liver immunopathology using parasitological, biochemical, histological, and immunohistochemical (IHC) evaluations. Methodology: Sixty female BALB/c mice were organized into six groups: GI (normal control), GII (infected, untreated), GIII (normal, SB-treated), GIV (infected, PZQ-treated), GV (infected, SB-treated), and GVI (infected, combined-treated). Worm burden, liver egg count, intestinal oogram, liver enzymes, liver histopathology, and high mobility group box 1 (HMGB1) expression were assessed.
Results
Combination therapy demonstrated the greatest reduction in total worm burden (61%) and hepatic egg count (1876.2 ± 434.50), with significant improvement in liver enzyme levels. Histopathological examination revealed a marked reduction in granuloma number (58.86%) and size (35.9%), accompanied by suppression of HMGB1 expression compared with monotherapies.
Conclusion
Although SB exhibited limited antiparasitic activity, it showed significant anti-fibrotic effects and may serve as a beneficial adjunct to praziquantel therapy.
Zitieren
APA
Hassan, R. E., Ramadan, M. E., Aboulfotouh, N. I., Sallam, R. A. A., Othman, B. H., & Awad, S. I. (2026). Evaluation of Sodium Butyrate as an Anti-fibrotic Agent in Experimental Schistosomiasis mansoni infection. Mansoura Medical Journal, 56(2). https://doi.org/10.58775/2735-3990.1604
Vancouver
Hassan RE, Ramadan ME, Aboulfotouh NI, Sallam RAA, Othman BH, Awad SI. Evaluation of Sodium Butyrate as an Anti-fibrotic Agent in Experimental Schistosomiasis mansoni infection. Mansoura Medical Journal. 2026;56(2). doi:10.58775/2735-3990.1604
BibTeX
@article{Hassan2026,
author = {Hassan, Rania Eladl and Ramadan, Manar Ezzelarab and Aboulfotouh, Nora Ibrahim and Sallam, Ramy Ahmed Abdelsalam and Othman, Basma Hamed and Awad, Soha Ibrahim},
title = {Evaluation of Sodium Butyrate as an Anti-fibrotic Agent in Experimental Schistosomiasis mansoni infection},
journal = {Mansoura Medical Journal},
year = {2026},
volume = {56},
number = {2},
doi = {10.58775/2735-3990.1604}
}
EUVIMED